Is pharma missing the boat on diagnostics?

Precision medicine is bringing pharma and diagnostics closer together, but there’s still a ways to go before the matchup is fully realized.

By Meagan Parrish • April 24, 2026

An ‘AI scientist’ can tackle drug R&D. What does that mean for pharma?

A new tool is giving researchers a “data center full of genius Ph.D. students in their pocket.”

By Alexandra Pecci • April 22, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine

The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy. 

By Gwendolyn Wu • April 22, 2026

Lilly’s CAR-T Kelonia deal cements Big Pharma’s in vivo push

The pharma giant’s second CAR-T deal this year, this one worth up to $7 billion, further solidifies what the industry sees as the future of genetic medicines.

By Michael Gibney • April 21, 2026

Roche’s DAC investment; Big Pharma’s lavish CEO bumps

Roche is investing in new cancer-fighting technology, and some of Big Pharma's CEOs notched some noteworthy pay hikes.

By PharmaVoice Staff • April 17, 2026

Can an LSD candidate do for anxiety what Spravato did for depression?

Definium Therapeutics is expecting late-stage data for two anxiety trials in the coming months, teeing up a potential approval.

By Meagan Parrish • April 17, 2026

Will cancer drugmakers ever conquer p53?

The protein is implicated in a wide swath of cancers, but harnessing it for drug R&D is still a major scientific challenge.

By Kelly Bilodeau • April 15, 2026

The era of Big Pharma’s one-size-fits-all pipeline is fading

Roche, AstraZeneca and Sanofi demonstrate how companies are following their own R&D paths.

By Kelly Bilodeau • April 13, 2026

Predictive analytics in pharma turns lab data into launch strategies

Explore how diagnostic insights become launch strategies with predictive analytics and real-world lab data.

April 13, 2026

Biotech’s IPO comeback; Trump’s tariff loophole for pharma

Biotech IPOs gain long-lost momentum, and pharma companies find a way around the White House’s harsh tariffs.

By PharmaVoice Staff • April 10, 2026

One doctor helped kickstart US nuclear medicine’s new wave. Now he’s refining it.

Dr. Ebrahim Delpassand, founder and CEO of RadioMedix, played a pivotal role in advancing nuclear medicine as a new-generation cancer treatment, but his work is far from finished.

By Michael Gibney • April 9, 2026

Women have awaited a revolution in menopause. It hasn’t arrived.

Persistent barriers are still hindering drug development for a host of menopause symptoms.

By Kelly Bilodeau • April 8, 2026

Boehringer Ingelheim’s confident new leap in the obesity market

With weight loss candidates still in the clinic, the company has launched a health unit aimed at the flourishing therapeutic area.

By Alexandra Pecci • April 7, 2026

Evommune bucked biotech IPO drought and is focused on the long game

Evommune went public late last year and is taking on stiff competition in immunology with a recent mid-stage clinical win.

By Michael Gibney • April 7, 2026

AI’s next trick? Revealing new disease targets for drug R&D

A wave of AI-driven platforms bucks the traditional approach of hunting for new molecules and instead focuses on pinpointing the underlying cause of disease.

By Meagan Parrish • April 3, 2026

Will Pfizer’s Lyme disease gamble pay off or set the space back?

As the disease spreads into new regions, the urgency for prevention is growing.

By Kelly Bilodeau • April 1, 2026

mRNA is poised to rise beyond infectious diseases, if it’s not derailed by R&D cuts

Research into areas like cancer could become collateral damage of a broader anti-mRNA push, according to a new study.

By Alexandra Pecci • March 31, 2026

Can Ocugen succeed where other gene therapy makers have struggled?

The biotech aims to quickly bring three gene therapies to market, and overcome the development and commercialization challenges that have dogged the space.

By Meagan Parrish • March 27, 2026

How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup

Cohen says he looked at around two dozen companies since Acorda wound down. Oryon Cell Therapies, with its funding, data and “autologous” approach, stood out amongst the crowd.

By Jacob Bell • March 26, 2026

Mixed signals cloud the orphan drug market

The field is making gains despite regulatory inconsistency, but rising competition from obesity candidates and evolving global pressures could erode orphan drugs’ market share.

By Kelly Bilodeau • March 25, 2026

Women in biotech hit a leadership plateau as board barriers persist

A new initiative from BioIndustry Association and AstraZeneca aims to boost representation on heavily dominated male boards.

By Alexandra Pecci • March 24, 2026

How AI is reshaping clinical trials

Human oversight remains crucial as the technology is leveraged in safety monitoring, boosting clinical trial diversity and more.

By Kelly Bilodeau • March 23, 2026

Gilead could potentially end HIV. But will it be able to?

After launching a PrEP medication that was 100% effective in clinical trials, the company is facing a complex global rollout and leveraging its network of partners for help.

By Meagan Parrish • March 20, 2026

Novartis acquisition spin-off pioneers RNA therapeutics for the heart

The newly launched Atrium Therapeutics will focus on precision RNA therapeutics for rare, genetic cardiomyopathies.

By Alexandra Pecci • March 19, 2026

As Chinese biotechs recognize their value, the bargain era may be over

Rising average upfront payments signal that buyers see value in Chinese assets.

By Kelly Bilodeau • March 18, 2026